December 7, 2021: Daré announced that the U.S. Food and Drug Administration (FDA) approved XACIATO™ [zah-she-AH-toe] (clindamycin phosphate) vaginal gel 2% for the treatment of bacterial vaginosis in females 12 years of age and older.

June 30, 2022: Organon (NYSE: OGN), a global women’s healthcare company, and Daré Bioscience announced the closing of an agreement whereby Organon licensed the global rights to XACIATO™ (clindamycin phosphate) vaginal gel 2%.

October 16, 2023: Daré announced the first shipment of XACIATO™ in the U.S. triggering a commercial milestone of $1.8 million.

Please see the Prescribing Information, Patient Information, and Instructions for Use.

Learn More:

Patient site: https://www.xaciato.com/

Provider site: https://organonpro.com/en-us/product/xaciato/overview/

ABOUT BACTERIAL VAGINOSIS¹

BV is the most common vaginal condition in women of reproductive age in the United States. The condition results from an overgrowth of certain bacteria, which upsets the balance of the natural vaginal microbiome and can lead to symptoms of odor or discharge. BV may self-resolve in up to 30% of women, but most symptomatic women require treatment. If left untreated, BV may lead to serious complications. BV has also been shown to disproportionately affect non-Hispanic Black and Mexican American women.

Footnotes:

^{1 Kairys N, et al. In: StatPearls. StatPearls Publishing; 2022. www.ncbi.nlm.nih.gov/books/NBK459216/, Accessed April 20, 2023.}